Top ▲
This section gives an overview of the disease, and where available shows the following:
More information can be found in the help pages.
✖Disease ID: | 578 | |
Name: | Lymphoma, non-hodgkin, familial | |
Associated with: | 4 targets | |
2 immuno-relevant ligands | ![]() |
Synonyms |
Non-Hodgkin lymphoma |
Description |
A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and lethargy. |
Database Links |
Disease Ontology:
DOID:0060060 OMIM: 605027 |
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖Caspase 10 |
TLR9 |
B-Raf proto-oncogene, serine/threonine kinase | |
References: | 3 |
regulator of G-protein signaling 5 | |
Comments: | RGS5 transcripts are greatly increased in eight subtypes of lymphoma. |
References: | 4 |
Click ligand name to view ligand summary page
Click the arrow in the final column to expand comments
More information can be found in the help pages.
✖Key to terms and symbols | Click ligand name to view ligand summary | Click column headers to sort | |||||||||||||||||||||||||
|
1. Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E. (2018) IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors. J Immunother, 41 (5): 224-231. [PMID:29683891]
2. Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, Stein H, Janz M, Dörken B, Mathas S. (2008) Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood, 112 (8): 3339-47. [PMID:18684866]
3. Lee JW, Yoo NJ, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ et al.. (2003) BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer, 89 (10): 1958-60. [PMID:14612909]
4. Sethakorn N, Dulin NO. (2013) RGS expression in cancer: oncomining the cancer microarray data. J Recept Signal Transduct Res, 33 (3): 166-71. [PMID:23464602]